Frequency of polymorphisms in the CYP2C9, VKORC1, and CYP4F2 genes related to the metabolism of Warfarin in healthy donors from Cali, Colombia.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
28 Jul 2023
28 Jul 2023
Historique:
medline:
31
7
2023
pubmed:
28
7
2023
entrez:
28
7
2023
Statut:
ppublish
Résumé
Alleles in the VKORC1, CYP2C9, and CYP4F2 genes can influence Warfarin dose requirement. We aimed to determine the frequency of the polymorphisms in these genes in healthy individuals from Cali, Colombia. Observational study where total blood was collected from 107 healthy donors who attended a higher educational institution in Cali, Colombia. Sanger sequencing of exons 2, 3, 5, and 7 of the CYP2C9 gene; the common promoter region of CYP (rs12777823); exon 11 of CPY4F2 and the polymorphism c.-1639G > A in the VKORC1 gene promoter was performed. CYP2C9*2, CYP2C9*3, CYP2C9*8, CYP2C9*9, CYP2C9*11, CYP4F2*3, rs12777823, and VKORC1*2 were detected. The latter had the highest frequency with 80 (74.8%) participants in a heterozygous or homozygous state. The least frequent allele was CYP2C9*11 with only 1 carrier. Combined haplotypes (VKORC1 *1/*2 or *2/*2 and CYP2C9 *1/*2 or *2/*2) were identified in 14 (13.7%) subjects. Both frequencies found in the VKORC1 and CYP2C9 alleles were similar to the ones reported for Latin Americans of European and Native American Ancestry. VKORC1*2 allele, the main genetic contributor to Warfarin dosing requirement, was the variant with the highest frequency (74.8% subjects, with a frequency of the alternative allele (A) of 50%). Our findings provide researchers with a greater insight regarding the frequency of common polymorphisms that affect anticoagulation treatment in the Cali (Colombia) population.
Identifiants
pubmed: 37505171
doi: 10.1097/MD.0000000000034204
pii: 00005792-202307280-00054
pmc: PMC10378978
doi:
Substances chimiques
Warfarin
5Q7ZVV76EI
Cytochrome P-450 CYP2C9
EC 1.14.13.-
Anticoagulants
0
Cytochrome P450 Family 4
EC 1.14.14.1
Vitamin K Epoxide Reductases
EC 1.17.4.4
CYP2C9 protein, human
EC 1.14.13.-
CYP4F2 protein, human
EC 1.14.14.78
VKORC1 protein, human
EC 1.17.4.4
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e34204Informations de copyright
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Johnson JA, Gong L, Whirl-Carrillo M, et al.; Clinical Pharmacogenetics Implementation Consortium. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther. 2011;90:625–9.
de Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013;110:1087–107.
Biswas M, Bendkhale S, Deshpande S, et al. Association between genetic polymorphisms of CYP2C9 and VKORC1 and safety and efficacy of warfarin: results of a 5 years audit. Indian Heart J. 2018;70(Suppl 3):S13–9.
Budnitz D, Lovegrove M, Shehab N, et al. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365:2002–12.
Wen Chang GS, Tan DSY. Using pharmacogenetic testing to tailor warfarin therapy: the Singapore experience and what the future holds. Eur Cardiol. 2020;15.
Bazan N, Sabry N, Rizk A, et al. Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism. Ir J Med Sci. 2014;183:161–72.
Johnson JA. Warfarin pharmacogenetics: a rising tide for its clinical value. Circulation. 2012;125:1964–6.
Lund K, Gaffney D, Spooner R, et al. Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates. Br J Haematol. 2012;158:256–61.
Takeuchi F, McGinnis R, Bourgeois S, et al. A genome-wide association study confirms VKORC1, CYP2C9, ACYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 2009;5:e1000433.
The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2006;355:11–20.
Drozda K, Pacanowski MA, Grimstein C, et al. Pharmacogenetic labeling of FDA-approved drugs: a regulatory retrospective. JACC Basic Transl Sci. 2018;3:545–9.
Kaye JB, Schultz LE, Steiner HE, et al. Warfarin pharmacogenomics in diverse populations. Pharmacotherapy. 2017;37:1150–63.
Lima M, Ribeiro GS, Mesquita ET, et al. CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients. Eur J Clin Pharmacol. 2008;64:9–15.
Alvarado AT, Muñoz AM, Loja B, et al. Estudio de las variantes alélicas CYP2C9*2 y CYP2C9*3 en muestras de población mestiza peruana. Biomedica. 2019;39:601–10.
Rodrigues-Soares F, Peñas-Lledó EM, Tarazona-Santos E, et al.; RIBEF Ibero-American Network of Pharmacogenetics and Pharmacogenomics. Genomic ancestry, CYP2D6, CYP2C9, and CYP2C19 among Latin Americans. Clin Pharmacol Ther. 2020;107:257–68.
Valentin II, Vazquez J, Rivera-Miranda G, et al. Predicción de las reducciones en la dosis de warfarina para pacientes Puertorriqueños basado en los genotipos combinados de CYP2C9 y VKORC1. Ann Pharmacother. 2012;46:208–18.
Scibona P, Redal MA, Garfi LG, et al. Prevalence of CYP2C9 and VKORC1 alleles in the Argentine population and implications for prescribing dosages of anticoagulants. Genet Mol Res. 2012;11:70–6.
Llerena A, Dorado P, O’Kirwan F, et al. Lower frequency of CYP2C9*2 in Mexican-Americans compared to Spaniards. Pharmacogenomics J. 2004;4:403–6.
Isaza C, Beltrán L, Henao J, et al. Factores genéticos y ambientales asociados con la respuesta a warfarina en pacientes colombianos. Biomedica. 2010;30:410–20.
Cifuentes RA, Murillo-Rojas J, Avella-Vargas E. Predicción de la sensibilidad a la warfarina con base en polimorfismos de los genes VKORC1 y CYP2C9 en pacientes colombianos. Biomedica. 2016;36:91–100.
Untergasser A, Cutcutache I, Koressaar T, et al. Primer3-new capabilities and interfaces. Nucleic Acids Res. 2012;40:e115–e115.
Xiong Y, Wang M, Fang K, et al. A systematic genetic polymorphism analysis of the CYP2C9 gene in four different geographical Han populations in mainland China. Genomics. 2011;97:277–81.
Li J, Yang W, Xie Z, et al. Impact of VKORC1, CYP4F2 and NQO1 gene variants on warfarin dose requirement in Han Chinese patients with catheter ablation for atrial fibrillation. BMC Cardiovasc Disord. 2018;18:96.
Kumar S, Stecher G, Li M, et al. MEGA X: molecular evolutionary genetics analysis across computing platforms. Mol Biol Evol. 2018;35:1547–9.
Johnson JA, Caudle KE, Gong L, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharmacol Ther. 2017;102:397–404.
Phan L, Zhang Y, Qiang W, et al. ALFA: allele frequency aggregator. National Center for Biotechnology Information, U.S. National Library of Medicine; 2020. Available at: www.ncbi.nlm.nih.gov/snp/docs/gsr/alfa/ .
Graffelman J, Camarena JM. Graphical tests for Hardy-Weinberg equilibrium based on the ternary plot. Hum Hered. 2007;65:77–84.
Limdi NA, Goldstein JA, Blaisdell JA, et al. Influence of CYP2C9 genotype on warfarin dose among African-Americans and European-Americans. Per Med. 2007;4:157–69.
Shaw K, Amstutz U, Kim RB, et al.; CPNDS Clinical Recommendation Group. Clinical practice recommendations on genetic testing of CYP2C9 and VKORC1 variants in warfarin therapy. Ther Drug Monit. 2015;37:428–36.
Singh O, Sandanaraj E, Subramanian K, et al. Influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in Asian patients. Drug Metab Pharmacokinet. 2011;26:130–6.
Perini JA, Struchiner CJ, Silva-Assunção E, et al. Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort. Clin Pharmacol Ther. 2010;87:417–20.
Dean L. Warfarin therapy and VKORC1 and CYP genotype. Bethesda, MD: National Center for Biotechnology Information (US); 2012. Available at: http://europepmc.org/books/NBK84174 .